Literature DB >> 6600579

Erythromycin in treatment of Campylobacter enteritis in children.

C H Pai, F Gillis, E Tuomanen, M I Marks.   

Abstract

Erythromycin ethylsuccinate therapy was compared with no treatment in a randomized, prospective trial of treatment of Campylobacter enteritis in infants and children. Patients received either erythromycin ethylsuccinate (N = 15), 40 mg/kg/day every six hours, for seven days or no treatment (N = 12). The mean age (5.5 v 3.7 years), sex ratio, and mean duration of illness before admission to study (5.5 v 6.4 days) of the two groups were similar. No difference was noted in the mean days to resolution of diarrhea (3.2 v 3.8 days). However, the mean duration of bacterial shedding was shorter in the treatment group (2.0 days) compared with the group without treatment (16.8 days). Bacteriologic relapse occurred in one patient in the treatment group, and three relapses occurred in the group without treatment. Two secondary cases occurred among household contacts, one in each group.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6600579     DOI: 10.1001/archpedi.1983.02140290072019

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  10 in total

1.  Early treatment of Campylobacter jejuni enteritis.

Authors:  M D Williams; J B Schorling; L J Barrett; S M Dudley; I Orgel; W C Koch; D S Shields; S M Thorson; J A Lohr; R L Guerrant
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

Review 2.  Pathophysiology of Campylobacter enteritis.

Authors:  R I Walker; M B Caldwell; E C Lee; P Guerry; T J Trust; G M Ruiz-Palacios
Journal:  Microbiol Rev       Date:  1986-03

3.  In vitro activity of josamycin, a macrolide antibiotic, against microaerophilic campylobacter.

Authors:  V Sticht-Groh; H Hof
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

4.  Recrudescent Campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well-characterized organism.

Authors:  Shahida Baqar; David R Tribble; Marya Carmolli; Katrin Sadigh; Frederic Poly; Chad Porter; Catherine J Larsson; Kristen K Pierce; Patricia Guerry; Michael Darsley; Beth Kirkpatrick
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

5.  Antimicrobial resistance and antimicrobial use associated with laboratory-confirmed cases of Campylobacter infection in two health units in Ontario.

Authors:  Anne E Deckert; Richard J Reid-Smith; Susan E Tamblyn; Larry Morrell; Patrick Seliske; Frances B Jamieson; Rebecca Irwin; Catherine E Dewey; Patrick Boerlin; Scott A McEwen
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  Susceptibility of Campylobacter species to metronidazole, its bioactive metabolites and tinidazole.

Authors:  R M Bannatyne; J Jackowski; M A Karmali
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

7.  In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam.

Authors:  P Van der Auwera; B Scorneaux
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

8.  Erythromycin-resistant Campylobacter infections in Thailand.

Authors:  D N Taylor; M J Blaser; P Echeverria; C Pitarangsi; L Bodhidatta; W L Wang
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

Review 9.  Severe acute diarrhea.

Authors:  Julia I Gore; Christina Surawicz
Journal:  Gastroenterol Clin North Am       Date:  2003-12       Impact factor: 3.806

Review 10.  Infections in day-care centers.

Authors:  F J Crosson; S B Black; C E Trumpp; M Grossman; C T Lé; A S Yeager
Journal:  Curr Probl Pediatr       Date:  1986-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.